Heink et al. 2017: Ibogaine Treatment Phenomenology Survey (5D-ASC) — Contexts of Use, Not Controlled Efficacy

Definition box

Definition: Heink A., Katsikas S., & Lange-Altman T. (2017) published *Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences* in the *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2017.1290855; PMID 28266890; *J Psychoactive Drugs* 49(3):201–208). This retrospective online survey (completed n≈27 after high attrition) used the 5D-ASC (five-dimensional Altered States of Consciousness) scale to characterize subjective ibogaine experiences and correlate ASC dimensions with self-reported outcomes (ability to make life changes, craving change, how “changed” the person felt). It also describes demographics and reasons for seeking treatment across medical and non-medical contexts. It is survey phenomenology, not an RCT, not a cure claim, and not proof of physician-supervised psychoactive IV ibogaine infusion. Most published clinical literature remains oral. Ibogaine is U.S. Schedule I and not FDA-approved. QTc/cardiac risk remains central regardless of how mystical the survey answers sound.

Quotable answer (56 words)

Heink, Katsikas, and Lange-Altman’s 2017 Journal of Psychoactive Drugs survey used the 5D-ASC scale in a small retrospective sample of people who had taken ibogaine, finding ASC dimensions correlated with self-reported life change and craving outcomes. Survey phenomenology is not controlled efficacy and not psychoactive IV ibogaine infusion proof. Schedule I; screen for QTc first.

Why this paper-spoke exists

Köck’s systematic review and similar maps frequently cite Heink 2017 as the “contexts of use / phenomenology survey.” SEO pages that only cite Brown/Mash detox numbers miss how people actually *find* and *frame* ibogaine—including informal and self-administration contexts that raise safety alarms. Soft CTA: /safety-and-screening → /apply. Pair with Brown qualitative follow-on (/blog/brown-alper-2018-depression-followup), AE review (/blog/ona-2022-ibogaine-adverse-events-review), and oral≠IV (/blog/ibogaine-oral-vs-iv).

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Heink A., Katsikas S., Lange-Altman T. *J Psychoactive Drugs*. 2017;49(3):201–208. doi 10.1080/02791072.2017.1290855. PMID 28266890 | | Type | Retrospective online survey / phenomenology | | Sample | N=27 completers discussed; authors note high attrition and limited generalizability | | Instrument | 5D-ASC altered-states scale + treatment-context questions | | Contexts | Medical and non-medical (self-administration / informal therapeutic settings appear in framing) | | Outcomes explored | Correlations between ASC dimensions and self-rated change, craving, life changes | | Route | Mixed/unknown by design (survey of past use)—not a controlled IV protocol paper | | What it is not | RCT; FDA approval; mortality study; psychoactive IV brand proof; cure claim |

Methods (plain language)

Researchers recruited people who had previously used ibogaine and asked them to complete validated ASC questionnaires plus questions about why they sought treatment, what the course looked like, and how they rated outcomes afterward. Retrospective internet surveys are vulnerable to selection bias (people with dramatic stories answer; people who died cannot).

Key findings (no hype)

• Participants tended to describe thematically similar post-treatment experiences.
• Positive correlations were reported between ASC dimensions and self-reported outcomes (life-change ability, craving-related ratings, overall sense of personal change).
• Demographics and motivations for seeking ibogaine are part of the paper’s contribution—useful for “who seeks this” literacy.
• Authors themselves flag high attrition and small n as limits on generalizability.
• The paper “explores possible utility” language—editorial pages must not upgrade that into proven efficacy.

Honest reading: ASC–outcome correlations in a tiny self-selected survey are hypothesis-generating phenomenology, not detox efficacy proof.

Contexts of use: why this matters for safety SEO

Heink’s framing includes people treated outside pristine research hospitals. That is exactly where Corkery-style fatality reviews and Ona AE syntheses find trouble: impure product, polypharmacy, no telemetry, no electrolyte plan (/blog/corkery-ibogaine-fatalities, /blog/ona-2022-ibogaine-adverse-events-review, /blog/cheap-ibogaine-clinic-red-flags). Survey romance without setting literacy is how YMYL content fails families.

Route honesty & entity clarity

A retrospective survey cannot establish route-specific efficacy for physician-supervised psychoactive IV ibogaine infusion. Most human clinical series in the 10-year inventory remain oral. Distinguish:

| Label | Meaning | |-------|---------| | Oral ibogaine literature | Dominant published clinical route | | Support IV (Mg, fluids) | Adjuncts—not the psychoactive drug | | Psychoactive IV ibogaine infusion | Brand entity under physician supervision |

Entity hub: /what-is-ibogaine-infusion.

Cardiac / YMYL context

5D-ASC scores do not measure QT intervals. Any page citing Heink for “people felt transformed” must still surface QTc risk (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-ecg-pre-infusion-checklist).

Limits and confounders

| Limit | Why it matters | |-------|----------------| | High attrition / small n | Unstable estimates | | Retrospective self-report | Memory and expectancy bias | | No control group | Cannot isolate drug vs setting vs time | | Mixed contexts | Safety non-comparable | | Not cardiac-instrumented | Zero QT data |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Survey proves ibogaine cures addiction” | False | | “ASC correlation = FDA evidence” | False | | “Proves psychoactive IV protocol” | False | | Useful phenomenology + context literacy? | Yes—with labels |

Soft CTA

How SEO should use Heink without overselling

Editorial rules for this spoke:

1. Lead with survey / phenomenology / small-n / high attrition—never “clinical trial proved.”
2. Keep contexts of use as the SEO value: people seek ibogaine in medical *and* informal settings; informal settings map onto fatality clusters.
3. Treat ASC–outcome correlations as hypothesis-generating, useful for integration psychology discussions (/blog/ibogaine-aftercare-integration) but useless as stand-alone efficacy.
4. Always exit to cardiac literacy (/safety-and-screening) rather than only to hopeful detox pages.
5. Distinguish Heink’s retrospective internet sample from prospective clinic observationals (Brown/Alper, Noller, Malcolm, Mash) and from MISTIC’s veteran TBI protocol.

Search snippets that say “study shows ibogaine users transform” without “retrospective survey, n=27, high attrition” fail YMYL. Transform the snippet: name the method class first.

Comparison to adjacent phenomenology papers

| Paper | Design | Why different | |-------|--------|---------------| | Heink 2017 | Retrospective online 5D-ASC survey | Contexts + ASC correlations; mixed settings | | Brown/Noller/Denenberg 2019 | SCQ + narratives from known OUD cohorts | Anchored to Brown–Alper / Noller samples (/blog/brown-alper-2018-depression-followup) | | Olash 2026 | Grounded theory on MISTIC veterans | Oral + IV Mg protocol narratives (/blog/mistic-subjective-experience) | | Davis mixed-method 2018 line | Persisting effects after detox | Different instrument/outcome framing |

Cite the right phenomenology paper for the right question; do not mash DOIs.

If survey stories are the hook, let screening be the next click: /safety-and-screening → /apply for supervised IV ibogaine infusion questions only.

FAQ

What is Heink 2017? A retrospective online survey/phenomenology paper using 5D-ASC in people with past ibogaine use (doi **10.1080/02791072.2017.1290855**).

How many people completed it? Authors discuss N=27 completers and note high attrition limiting generalizability.

Did ASC scores correlate with outcomes? Yes—positive correlations with self-reported life change/craving-related ratings were reported; still not controlled efficacy.

Is this an RCT? No.

Does it prove IV ibogaine infusion works? No. Survey of past use; not psychoactive IV brand proof.

Are informal/self-administration contexts safe? Fatality and AE literature argue unsupervised settings increase risk—see Corkery/Ona spokes.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Heink A., Katsikas S., Lange-Altman T. *J Psychoactive Drugs*. 2017;49(3):201–208. doi: 10.1080/02791072.2017.1290855. PMID: 28266890.
2. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
3. Ona G. et al. *Psychopharmacology*. 2022. doi: 10.1007/s00213-021-05964-y.
4. Corkery J.M. *Prog Brain Res*. 2018;242:217–257. doi: 10.1016/bs.pbr.2018.08.005.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Heink 2017 is a small retrospective survey—not a cure claim and not psychoactive IV ibogaine efficacy proof.